Lv1
30 积分 2022-05-10 加入
Advances in Targeting HER2 across Cancer Subtypes – A Pan-tumor Approach
1天前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
1天前
已完结
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes
7天前
已完结
CCL3+ neutrophil signature predicts response to neoadjuvant toripalimab plus chemotherapy in patients with hypopharyngeal squamous cell carcinoma: A phase II trial
8天前
已完结
Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer
8天前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
10天前
已完结
Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody–drug conjugates arrived?
10天前
已完结
Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial
25天前
已完结
Antibody–drug conjugates come of age in oncology
1个月前
已完结
皖公网安备34019202002308
